PYC commences new study on drug for eye condition Retinitis Pigmentosa type 11
PYC Therapeutics Ltd has begun a new trial into the safety and efficacy of its VP-001 drug which has been fast tracked by the FDA.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No Corporate Spotlight currently available.